Benedikt L Proffen1, Patrick Vavken2, Carla M Haslauer3, Braden C Fleming4, Chad E Harris5, Jason T Machan6, Martha M Murray3. 1. Department of Orthopaedic Surgery, Boston Children's Hospital, Boston, Massachusetts, USA benedikt.proffen@childrens.harvard.edu. 2. Department of Orthopaedic Surgery, Boston Children's Hospital, Boston, Massachusetts, USA Department of Orthopaedic Surgery, University Hospital Basel, Switzerland. 3. Department of Orthopaedic Surgery, Boston Children's Hospital, Boston, Massachusetts, USA. 4. Department of Orthopaedics, Warren Alpert Medical School of Brown University/Rhode Island Hospital, Providence, Rhode Island, USA. 5. Department of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts, USA. 6. Department of Orthopaedics, Warren Alpert Medical School of Brown University/Rhode Island Hospital, Providence, Rhode Island, USA Biostatistics, Rhode Island Hospital, Providence, Rhode Island, USA.
Abstract
BACKGROUND: Coculture of mesenchymal stem cells (MSCs) from the retropatellar fat pad and peripheral blood has been shown to stimulate anterior cruciate ligament (ACL) fibroblast proliferation and collagen production in vitro. Current techniques of bioenhanced ACL repair in animal studies involve adding a biologic scaffold, in this case an extracellular matrix-based scaffold saturated with autologous whole blood, to a simple suture repair of the ligament. Whether the enrichment of whole blood with MSCs would further improve the in vivo results of bioenhanced ACL repair was investigated. HYPOTHESIS: The addition of MSCs derived from adipose tissue or peripheral blood to the blood-extracellular matrix composite, which is used in bioenhanced ACL repair to stimulate healing, would improve the biomechanical properties of a bioenhanced ACL repair after 15 weeks of healing. STUDY DESIGN: Controlled laboratory study. METHODS: Twenty-four adolescent Yucatan mini-pigs underwent ACL transection followed by (1) bioenhanced ACL repair, (2) bioenhanced ACL repair with the addition of autologous adipose-derived MSCs, and (3) bioenhanced ACL repair with the addition of autologous peripheral blood derived MSCs. After 15 weeks of healing, the structural properties of the ACL (yield load, failure load, and linear stiffness) were measured. Cell and vascular density were measured in the repaired ACL via histology, and its tissue structure was qualitatively evaluated using the advanced Ligament Maturity Index. RESULTS: After 15 weeks of healing, there were no significant improvements in the biomechanical or histological properties with the addition of adipose-derived MSCs. The only significant change with the addition of peripheral blood MSCs was an increase in knee anteroposterior laxity when measured at 30° of flexion. CONCLUSION: These findings suggest that the addition of adipose or peripheral blood MSCs to whole blood before saturation of an extracellular matrix carrier with the blood did not improve the functional results of bioenhanced ACL repair after 15 weeks of healing in the pig model. CLINICAL RELEVANCE: Whole blood represents a practical biologic additive to ligament repair, and any other additive (including stem cells) should be demonstrated to be superior to this baseline before clinical use is considered.
BACKGROUND: Coculture of mesenchymal stem cells (MSCs) from the retropatellar fat pad and peripheral blood has been shown to stimulate anterior cruciate ligament (ACL) fibroblast proliferation and collagen production in vitro. Current techniques of bioenhanced ACL repair in animal studies involve adding a biologic scaffold, in this case an extracellular matrix-based scaffold saturated with autologous whole blood, to a simple suture repair of the ligament. Whether the enrichment of whole blood with MSCs would further improve the in vivo results of bioenhanced ACL repair was investigated. HYPOTHESIS: The addition of MSCs derived from adipose tissue or peripheral blood to the blood-extracellular matrix composite, which is used in bioenhanced ACL repair to stimulate healing, would improve the biomechanical properties of a bioenhanced ACL repair after 15 weeks of healing. STUDY DESIGN: Controlled laboratory study. METHODS: Twenty-four adolescent Yucatan mini-pigs underwent ACL transection followed by (1) bioenhanced ACL repair, (2) bioenhanced ACL repair with the addition of autologous adipose-derived MSCs, and (3) bioenhanced ACL repair with the addition of autologous peripheral blood derived MSCs. After 15 weeks of healing, the structural properties of the ACL (yield load, failure load, and linear stiffness) were measured. Cell and vascular density were measured in the repaired ACL via histology, and its tissue structure was qualitatively evaluated using the advanced Ligament Maturity Index. RESULTS: After 15 weeks of healing, there were no significant improvements in the biomechanical or histological properties with the addition of adipose-derived MSCs. The only significant change with the addition of peripheral blood MSCs was an increase in knee anteroposterior laxity when measured at 30° of flexion. CONCLUSION: These findings suggest that the addition of adipose or peripheral blood MSCs to whole blood before saturation of an extracellular matrix carrier with the blood did not improve the functional results of bioenhanced ACL repair after 15 weeks of healing in the pig model. CLINICAL RELEVANCE: Whole blood represents a practical biologic additive to ligament repair, and any other additive (including stem cells) should be demonstrated to be superior to this baseline before clinical use is considered.
Authors: Michael J Eagan; Patricia A Zuk; Ke-Wei Zhao; Benjamin E Bluth; Elyse J Brinkmann; Benjamin M Wu; David R McAllister Journal: J Tissue Eng Regen Med Date: 2011-09-22 Impact factor: 3.963
Authors: Martha M Murray; Kurt P Spindler; Eduardo Abreu; John A Muller; Arthur Nedder; Mark Kelly; John Frino; David Zurakowski; Maria Valenza; Brian D Snyder; Susan A Connolly Journal: J Orthop Res Date: 2007-01 Impact factor: 3.494
Authors: Judith E Glim; Marjolein van Egmond; Frank B Niessen; Vincent Everts; Robert H J Beelen Journal: Wound Repair Regen Date: 2013-08-08 Impact factor: 3.617
Authors: Ahmad Y Sheikh; Bruno C Huber; Kazim H Narsinh; Joshua M Spin; Koen van der Bogt; Patricia E de Almeida; Katherine J Ransohoff; Daniel L Kraft; Giovanni Fajardo; Diego Ardigo; Julia Ransohoff; Daniel Bernstein; Michael P Fischbein; Robert C Robbins; Joseph C Wu Journal: Arterioscler Thromb Vasc Biol Date: 2011-10-27 Impact factor: 8.311
Authors: Joana P Miranda; Elysse Filipe; Ana Sofia Fernandes; Joana M Almeida; José P Martins; Alexandre De la Fuente; Miguel Abal; Rita N Barcia; Pedro Cruz; Helder Cruz; Matilde Castro; Jorge M Santos Journal: Cell Transplant Date: 2013-12-30 Impact factor: 4.064
Authors: Giuseppe Pintucci; Scott Froum; Jared Pinnell; Paolo Mignatti; Shahin Rafii; David Green Journal: Thromb Haemost Date: 2002-11 Impact factor: 5.249
Authors: Koen E A van der Bogt; Sonja Schrepfer; Jin Yu; Ahmad Y Sheikh; Grant Hoyt; Johannes A Govaert; Jeffrey B Velotta; Christopher H Contag; Robert C Robbins; Joseph C Wu Journal: Transplantation Date: 2009-03-15 Impact factor: 4.939
Authors: Braden C Fleming; Kurt P Spindler; Matthew P Palmer; Elise M Magarian; Martha M Murray Journal: Am J Sports Med Date: 2009-03-31 Impact factor: 6.202
Authors: Ryan J Warth; Paul G Shupe; Xueqin Gao; Mohammad Syed; Walter R Lowe; Johnny Huard; Christopher D Harner Journal: Clin Orthop Relat Res Date: 2020-03 Impact factor: 4.755
Authors: Martha M Murray; Brett M Flutie; Leslie A Kalish; Kirsten Ecklund; Braden C Fleming; Benedikt L Proffen; Lyle J Micheli Journal: Orthop J Sports Med Date: 2016-11-21